PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
Chugai Press Release - 2 days (NewA1)
|
atezolizumab Sensitive: A1 - Approval
Chugai Press Release - 2 days - (New A1)
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
NICE - 3 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
NICE - 3 days - (New A2)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
Precision Oncology News - 2 weeks (NewA1)
|
durvalumab Sensitive: A1 - Approval
Precision Oncology News - 2 weeks - (New A2)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks (NewC2)
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks - (New C3)
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Urothelial Cancer
|
PD-L1 expression
|
Urothelial Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
avelumab + axitinib Sensitive: A1 - Approval
|
avelumab + axitinib Sensitive: A1 - Approval
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Urothelial Cancer
|
PD-L1 expression
|
Urothelial Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Cancer
|
PD-L1 expression
|
Esophageal Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Urothelial Cancer
|
PD-L1 expression
|
Urothelial Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
pembrolizumab + bevacizumab Sensitive: A1 - Approval
|
pembrolizumab + bevacizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
PD-L1 expression
|
Oral Cancer
|
PD-L1 expression
|
Oral Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Oropharyngeal Cancer
|
PD-L1 expression
|
Oropharyngeal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
ADX-2191 Sensitive: A2 - Guideline
|
ADX-2191 Sensitive: A2 - Guideline
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
PD-L1 expression
|
Gastric Adenocarcinoma
|
PD-L1 expression
|
Gastric Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Bladder Cancer
|
PD-L1 expression
|
Bladder Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Bladder Cancer
|
PD-L1 expression
|
Bladder Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Head and Neck Cancer
|
PD-L1 expression
|
Head and Neck Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 expression
|
Lung Non-Small Cell Squamous Cancer
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 expression
|
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Vulvar Cancer
|
PD-L1 expression
|
Vulvar Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Gastric Adenocarcinoma
|
PD-L1 expression
|
Gastric Adenocarcinoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
Immunotherapy Sensitive: A2 - Guideline
|
Immunotherapy Sensitive: A2 - Guideline
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Clear Cell Renal Cell Carcinoma
|
PD-L1 expression
|
Clear Cell Renal Cell Carcinoma
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
PD-L1 expression
|
Small Cell Lung Cancer
|
PD-L1 expression
|
Small Cell Lung Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Melanoma
|
PD-L1 expression
|
Melanoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
sugemalimab Sensitive: B - Late Trials
|
sugemalimab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
PD-L1 expression
|
Ovarian Cancer
|
PD-L1 expression
|
Ovarian Cancer
|
bevacizumab + atezolizumab Resistant: B - Late Trials
|
bevacizumab + atezolizumab Resistant: B - Late Trials
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
nivolumab + cabozantinib tablet Sensitive: B - Late Trials
|
nivolumab + cabozantinib tablet Sensitive: B - Late Trials
|
PD-L1 expression
|
Urothelial Cancer
|
PD-L1 expression
|
Urothelial Cancer
|
avelumab Sensitive: B - Late Trials
|
avelumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Urothelial Cancer
|
PD-L1 expression
|
Urothelial Cancer
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Melanoma
|
PD-L1 expression
|
Melanoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Melanoma
|
PD-L1 expression
|
Melanoma
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Bladder Cancer
|
PD-L1 expression
|
Bladder Cancer
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Ovarian Cancer
|
PD-L1 expression
|
Ovarian Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Ovarian Cancer
|
PD-L1 expression
|
Ovarian Cancer
|
CPB Sensitive: B - Late Trials
|
CPB Sensitive: B - Late Trials
|
PD-L1 expression
|
Cutaneous Melanoma
|
PD-L1 expression
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
nivolumab + bevacizumab Sensitive: B - Late Trials
|
nivolumab + bevacizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
MT-6402 Sensitive: B - Late Trials
|
MT-6402 Sensitive: B - Late Trials
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
pembrolizumab + lenvatinib Sensitive: B - Late Trials
|
pembrolizumab + lenvatinib Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
cemiplimab Sensitive: B - Late Trials
|
cemiplimab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
LUAD
|
PD-L1 expression
|
LUAD
|
atezolizumab Sensitive: C1 - Off-label
|
atezolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Malignant Pleural Mesothelioma
|
PD-L1 expression
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
durvalumab Sensitive: C1 - Off-label
|
durvalumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Salivary Gland Cancer
|
PD-L1 expression
|
Salivary Gland Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
BCC
|
PD-L1 expression
|
BCC
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Anal Carcinoma
|
PD-L1 expression
|
Anal Carcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Prostate Cancer
|
PD-L1 expression
|
Prostate Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Rectal Cancer
|
PD-L1 expression
|
Rectal Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Kidney Cancer
|
PD-L1 expression
|
Kidney Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 expression
|
Gastroesophageal Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Squamous Cell Skin Cancer
|
PD-L1 expression
|
Squamous Cell Skin Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Prostate Cancer
|
PD-L1 expression
|
Prostate Cancer
|
durvalumab Sensitive: C1 - Off-label
|
durvalumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Bladder Cancer
|
PD-L1 expression
|
Bladder Cancer
|
durvalumab Sensitive: C1 - Off-label
|
durvalumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Biliary Tract Cancer
|
PD-L1 expression
|
Biliary Tract Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|